1
|
Saito K, Goda R, Arai K, Asahina K, Kawabata M, Uchiyama H, Andou T, Shimizu H, Takahara K, Kakehi M, Yamauchi S, Nitta SI, Suga T, Fujita H, Ishikawa R, Saito Y. Interlaboratory evaluation of LC-MS-based biomarker assays. Bioanalysis 2024; 16:389-402. [PMID: 38334082 DOI: 10.4155/bio-2023-0173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/10/2024] Open
Abstract
Validation of biomarker assays is crucial for effective drug development and clinical applications. Interlaboratory reproducibility is vital for reliable comparison and combination of data from different centers. This review summarizes interlaboratory studies of quantitative LC-MS-based biomarker assays using reference standards for calibration curves. The following points are discussed: trends in reports, reference and internal standards, evaluation of analytical validation parameters, study sample analysis and normalization of biomarker assay data. Full evaluation of these parameters in interlaboratory studies is limited, necessitating further research. Some reports suggest methods to address variations in biomarker assay data among laboratories, facilitating organized studies and data combination. Method validation across laboratories is crucial for reducing interlaboratory differences and reflecting target biomarker responses.
Collapse
Affiliation(s)
- Kosuke Saito
- National Institute of Health Sciences, Kanagawa, Japan
| | - Ryoya Goda
- Daiichi Sankyo Company Ltd, Tokyo, Japan
| | - Koji Arai
- LSI Medience Corporation, Tokyo, Japan
| | | | | | | | | | | | | | | | | | | | | | | | - Rika Ishikawa
- National Institute of Health Sciences, Kanagawa, Japan
| | - Yoshiro Saito
- National Institute of Health Sciences, Kanagawa, Japan
| |
Collapse
|
2
|
Preijers FWMB, van der Velden VHJ, Preijers T, Brooimans RA, Marijt E, Homburg C, van Montfort K, Gratama JW. Fifteen years of external quality assessment in leukemia/lymphoma immunophenotyping in The Netherlands and Belgium: A way forward. CYTOMETRY PART B-CLINICAL CYTOMETRY 2015; 90:267-78. [PMID: 26102096 DOI: 10.1002/cyto.b.21266] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/02/2014] [Accepted: 06/19/2015] [Indexed: 11/06/2022]
Abstract
In 1985, external quality assurance was initiated in the Netherlands to reduce the between-laboratory variability of leukemia/lymphoma immunophenotyping and to improve diagnostic conclusions. This program consisted of regular distributions of test samples followed by biannual plenary participant meetings in which results were presented and discussed. A scoring system was developed in which the quality of results was rated by systematically reviewing the pre-analytical, analytical, and post-analytical assay stages using three scores, i.e., correct (A), minor fault (B), and major fault (C). Here, we report on 90 consecutive samples distributed to 40-61 participating laboratories between 1998 and 2012. Most samples contained >20% aberrant cells, mainly selected from mature lymphoid malignancies (B or T cell) and acute leukemias (myeloid or lymphoblastic). In 2002, minimally required monoclonal antibody (mAb) panels were introduced, whilst methodological guidelines for all three assay stages were implemented. Retrospectively, we divided the study into subsequent periods of 4 ("initial"), 4 ("learning"), and 7 years ("consolidation") to detect "learning effects." Uni- and multivariate models showed that analytical performance declined since 2002, but that post-analytical performance improved during the entire period. These results emphasized the need to improve technical aspects of the assay, and reflected improved interpretational skills of the participants. A strong effect of participant affiliation in all three assay stages was observed: laboratories in academic and large peripheral hospitals performed significantly better than those in small hospitals. © 2015 International Clinical Cytometry Society.
Collapse
Affiliation(s)
- Frank W M B Preijers
- Laboratory of Hematology, Department of Laboratory Medicine, Radboud UMC, Nijmegen, The Netherlands
| | | | - Tim Preijers
- Laboratory of Hematology, Department of Laboratory Medicine, Radboud UMC, Nijmegen, The Netherlands
| | - Rik A Brooimans
- Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - Erik Marijt
- Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands
| | - Christa Homburg
- Department of Immunocytology, Sanquin Blood Supply, Amsterdam, The Netherlands
| | - Kees van Montfort
- Department of Trials and Statistics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - Jan W Gratama
- Department of Internal Oncology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
| | | |
Collapse
|
3
|
Brando B, Gatti A, Chianese R, Gratama JW. Twenty years of external quality assurance in clinical cell analysis--a tribute to Jean-Luc D'Hautcourt. CYTOMETRY PART B-CLINICAL CYTOMETRY 2007; 72:2-7. [PMID: 17177196 DOI: 10.1002/cyto.b.20154] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
External quality assurance (EQA) programs in clinical cell analysis are now a consolidated item of laboratory practice. All the flow cytometric testings with an impact on clinical decision making have been submitted to regular EQA programs during the last 20 years, and this has produced internationally homogeneous guidelines, with a remarkable improvement in result reproducibility.Jean-Luc D'Hautcourt was a pioneer in this field, and his valuable contributions to flow cytometric method standardization and to the dissemination of the educational aspects of EQA programs are recognized. The different methodological approaches undertaken in the United States and Europe are discussed. The educational role of SIHON in the Benelux Countries and of UKNEQAS for Leucocyte Immunophenotyping worldwide is emphasized. Accredited and accreditating EQA programs require an impressive degree of organization and technical knowledge, so that only major international providers can afford such a task nowadays. However, small local studies still provide the necessary stimulus to the continuous improvement of the scientifical aspects of EQA schemes.
Collapse
Affiliation(s)
- Bruno Brando
- Haematology Laboratory and Transfusion Center, Legnano Hospital, Via Candiani 2, 20025 Legnano, Milan, Italy.
| | | | | | | |
Collapse
|
4
|
Buhr T, Länger F, Schlué J, von Wasielewski R, Lehmann U, Braumann D, Kreipe H. Reliability of lymphoma classification in bone marrow trephines. Br J Haematol 2002; 118:470-6. [PMID: 12139734 DOI: 10.1046/j.1365-2141.2002.03605.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The aim of this study was to test and establish the accuracy and reliability of lymphoma classification in bone marrow trephines according to the new World Health Organization (WHO) classification by considering predominantly the morphology and immunophenotype. Therefore, we retrospectively compared lymphoma diagnoses, rendered exclusively on bone marrow trephines without knowledge of lymph node diagnosis in 124 patients, with the results of the reference centres that had reviewed lymph node (n = 90) or extranodal biopsies (n = 34). The overall concordance rate was higher than 85% and 91%, respectively, when patients with discordant malignancy grades were excluded. The concordance rate for low-grade B-cell lymphomas was 93% and for high-grade B-cell lymphomas 84%. The main reasons for discordant diagnoses were divergent immunophenotypes among low-grade B-cell lymphomas (6 out of 81, i.e. 7.4%) and discrepant malignancy grades within high-grade B-cell lymphomas (6 out of 31, i.e. 19.4%). No relationship between discordant diagnoses and chemotherapy given during the course of the disease with the site of biopsy (i.e. lymph nodes, extranodal sites) was noted. We conclude from our results that bone marrow trephines are a reliable tool, not only for establishing bone marrow infiltration, but also for the subtyping of lymphomas.
Collapse
Affiliation(s)
- Thomas Buhr
- Institute of Pathology, Hannover Medical University, Carl-Neuberg-Strasse 1, D-30625 Hannover, Germany.
| | | | | | | | | | | | | |
Collapse
|
5
|
Abstract
In the past decade, cellular immunophenotyping has become a new discipline in diagnostic haematology and immunology, and is invaluable in the rapid diagnosis of leukaemia and monitoring disease progression in human immunodeficiency virus infected individuals. The introduction of bench top flow cytometers has meant that immunophenotyping is now also used for the quantitation of CD34(+) peripheral blood stem cells (PBSCs) to ensure the correct timing and adequacy of haematopoietic progenitor cell harvests. Furthermore, flow cytometry has become an important tool for the counting of leucocytes in blood components after leucocyte depletion. Because this new discipline is now such a major diagnostic and prognostic tool in the clinical arena, its use must be subject to both internal and external quality control. Such a requirement was first recognised as early as 1986 when an Inter-Regional Quality Assessment Scheme (IRQAS) was initiated for laboratories that undertook the immunocytochemical diagnosis of leukaemia using the alkaline phosphates anti-alkaline phosphatase technique. This programme began with around 25 UK laboratories. In 1990, after the introduction of two more programmes (one for leukaemia diagnosis using UV microscopy and latterly flow cytometry, and one for the enumeration of CD4(+) T cells) the IRQAS achieved UK National External Quality Assessment Scheme (UK NEQAS) status and changed its title to UK NEQAS for Leucocyte Immunophenotyping. In the past decade the once small IRQAS programme has evolved into the largest international scheme of its kind, providing EQA to over 650 laboratories world wide for leukaemia immunophenotyping, lymphocyte subset analysis, PBSCs, and more recently low level leucocyte counting. Over the years, this EQA programme has highlighted important problems, such as the inappropriate use of fluorochromes and antibody titre, and the identification of effective gating strategies, all of which have contributed directly to the high interlaboratory variations seen in cellular immunophenotyping. Furthermore, particularly in absolute counting of lymphocyte subsets, PBSCs, and the enumeration of low numbers of leucocytes, UK NEQAS for Leucocyte Immunophenotyping programmes have been instrumental in highlighting the differences that occur between single and dual platform flow cytometric technologies. As a result of these findings, UK NEQAS for Leucocyte Immunophenotyping has helped to reduce the variation seen on an interlaboratory basis and enabled greater standardisation both in the UK and internationally. These advances have been attributable to the development, by UK NEQAS for Leucocyte Immunophenotyping, of a unique whole blood stabilising process that ensures the retention of the physical characteristics (both light scatter and antigenic profile) required of cells to ensure successful cellular immunophenotyping. This major technological advancement has enabled the distribution of specimens for EQA purposes on a global scale that have minimal matrix effect and behave in a manner identical to fresh blood for several months after stabilisation.
Collapse
Affiliation(s)
- J T Reilly
- UK NEQAS for Leucocyte Immunophenotyping, Department of Haematology, Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, UK.
| | | |
Collapse
|
6
|
Kluin-Nelemans J, Van Wering E, Van Der Schoot C, Adriaansen H, Van'T Veer M, Van Dongen J, Gratama J. SIHONSCORE: a scoring system for external quality control of leukaemia/lymphoma immunophenotyping measuring all analytical phases of laboratory performance. Br J Haematol 2001; 112:337-43. [PMID: 11167826 DOI: 10.1046/j.1365-2141.2001.02500.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
For the diagnosis of leukaemia and leukaemic lymphoma, clinicians frequently have to rely on the results of immunophenotyping. To improve the quality of these results, the Dutch Foundation for Immunophenotyping of Haematological Malignancies (SIHON) initiated external quality rounds in 1986. Over a period of more than 10 years, this has led to improvements in the interpretation of immunophenotyping results. However, the evaluation of results focused mainly on the correctness of the interpretation of the immunophenotypical data, leaving the preceding analytical phases unevaluated. Therefore, in 1996 SIHON developed a more comprehensive scoring system, called SIHONSCORE, covering all three phases of immunophenotyping, namely the pre-analytical (i.e. choice of the staining panels), analytical (i.e. the technical part consisting of sample preparation, data acquisition and analysis) and the post-analytical phase (i.e. the interpretation) of the laboratory process. Here, we report how SIHONSCORE was successfully applied to three consecutive external quality rounds consisting of a total of nine different cases tested. For laboratory certification, participation in external quality control programmes is required. Evidently, criteria are needed to define the minimum acceptable performance of a certified laboratory. With SIHONSCORE, a useful instrument is obtained evaluating all phases of the performance of laboratories in leukaemia and lymphoma immunophenotyping.
Collapse
Affiliation(s)
- J Kluin-Nelemans
- Department of Haematology, Leiden University Medical Centre, Leiden.
| | | | | | | | | | | | | |
Collapse
|
7
|
Gratama JW, Bolhuis RL, Van 't Veer MB. Quality control of flow cytometric immunophenotyping of haematological malignancies. CLINICAL AND LABORATORY HAEMATOLOGY 1999; 21:155-60. [PMID: 10448596 DOI: 10.1046/j.1365-2257.1999.00214.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Immunophenotyping of haematological malignancies has developed as a clinically valuable but technically complicated diagnostic procedure. It involves a variety of methodological features, in-process strategic judgements and an extensive knowledge of clinical, morphological and other laboratory features of the disease processes under study. We discuss the various internal quality control steps necessary to guarantee reliable results with respect to instrument set-up and calibration; sample preparation; selection and validation of monoclonal antibody panels; and flow cytometric data acquisition, analysis and interpretation of results. The quality of the entire procedure is documented by the analysis of representative specimens in the setting of an external quality assurance programme.
Collapse
Affiliation(s)
- J W Gratama
- Department of Clinical and Tumor Immunology, University Hospital, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
| | | | | |
Collapse
|
8
|
Höffkes HG, Schmidtke G, Uppenkamp M, Schmücker U. Multiparametric immunophenotyping of B cells in peripheral blood of healthy adults by flow cytometry. CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY 1996; 3:30-6. [PMID: 8770500 PMCID: PMC170243 DOI: 10.1128/cdli.3.1.30-36.1996] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
The investigation of patients suffering from malignant lymphomas of the B-cell type requires flow cytometric immunophenotyping. Several reports described the expression of almost all B lineage antigens on normal and abnormal B lymphocytes. Thus, immunophenotyping of lymphomas must be interpreted in the context of the reference values obtained for healthy control individuals. For this purpose multiparametric flow cytometric analysis offers the unique feature for lymphocyte subset analysis. In the present study B lymphocytes in the peripheral blood of healthy adults were investigated by multiparametric flow cytometric immunophenotyping for the detection of the frequency (in percent) of antigens provided by the revised European-American classification of lymphoid neoplasms (REAL) classification. Thus, 84 healthy adults were investigated and grouped by age (average ages were as follows: group 1, 25.38 years; group 2, 33.86 years; group 3, 44.17 years; group 4, 55.67 years; group 5, 66.67 years). Analysis was done for surface immunoglobulins (kappa and lambda chains of immunoglobulin M [IgM] and IgD) as well as CD10, CD11c, CD23, CD38, CD103, FMC-7, and B-B4. Three-color immunophenotyping was performed for kappa/CD19/CD5, lambda/CD19/CD5, surface IgM/surface IgD/CD19, FMC-7/CD19/CD5, CD103/CD11c/CD19, CD10/CD23/CD19, and CD38/B-B4/CD19 by live gating of CD19+ events (n = 2,000). Although some numerical differences could be obtained for the different groups, statistical differences (P < 0.005) could only be obtained for the CD19+/CD5+ B-cell subset, which was decreased in the elderly patients (group 5). The established two-color and three-color stainings will serve as a basis for future multiparametric immunophenotyping of abnormal lymphocytes (e.g., for patients suffering from non-Hodgkin's lymphoma of the B-cell type).
Collapse
Affiliation(s)
- H G Höffkes
- Department of Medicine, University of Essen, Germany
| | | | | | | |
Collapse
|
9
|
Höffkes HG, Schmidtke G, Schmücker U, Uppenkamp M, Brittinger G. Immunophenotyping of B lymphocytes by multiparametric flow cytometry in bone marrow aspirates of healthy adults. Ann Hematol 1995; 71:123-8. [PMID: 7548330 DOI: 10.1007/bf01702647] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Establishing reference ranges by multiparametric immunophenotyping of mature B cells in bone marrow of healthy adults is of interest because the detection of bone marrow infiltration and persistence of light chain restriction, as well as discrimination between reactive and malignant lymphocytes are important applications of B-cell immunophenotyping. To determine the pattern of antigens as expressed by malignant mature B lymphocytes in the present study, bone marrow aspirates of healthy adults were investigated for the presence and percentage frequency of those antigens as defined for immunophenotyping of B cells by the REAL Classification. For this purpose, analysis of CD19-positive B lymphocytes by 'live gate' analysis was performed. The established two-color as well as three-color stainings will serve as a basis for future investigations designed to test multiparametric analysis of B lymphocytes in bone marrow aspirates. All investigated antibodies stained with varying percentage frequency on B-cell subtypes, and no statistical significant difference was found between bone marrow aspirates of women and those of men. On the basis of this analysis, all the reported lineage antigen combinations are present both in malignant B lymphocytes and in normal B cells in considerable percentage frequency. These findings are of importance for follow-up investigations of patients with non-Hodgkin's lymphomas by multiparametric immunophenotyping.
Collapse
Affiliation(s)
- H G Höffkes
- University of Essen, Department of Medicine, Germany
| | | | | | | | | |
Collapse
|
10
|
Segeren CM, de Jong-Gerrits GC, van 't Veer MB. AML-MO: clinical entity or waste basket for immature blastic leukemias? A description of 14 patients. Dutch Slide Review Committee of Leukemias in Adults. Ann Hematol 1995; 70:297-300. [PMID: 7632808 DOI: 10.1007/bf01696615] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
In the period from August 1991 to August 1994, the Dutch Slide Review Committee of Adult Leukemias classified 14 leukemias as AML-M0. We reviewed the clinical characteristics and response to therapy of these patients. Eight patients were male. Patients' age ranged from 7 to 77 years (medium age 62 years). There was a striking homogeneity in morphological appearance of the blasts, being small to medium-sized round cells with often an eccentric nucleus with fine chromatin, several distinct nucleoli, and a high nucleo-cytoplasmic ratio. In addition to myeloid-associated markers such as CD13 and CD33, the blasts of all patients were positive for CD34 and HLA-DR, pointing to their immature differentiation stage. TdT was present in the blasts of 71%, CD7 was positive in the blasts of 42% of the patients. No consistent cytogenetic abnormalities were found. With respect to the treatment outcome, four patients achieved a complete remission after remission-induction treatment. The median survival was 4.5 months. Our present study shows AML-M0 to be an immature leukemia, uniform in morphology and immunological phenotype, with no consistent cytogenetic phenotype and with a poor clinical outcome.
Collapse
Affiliation(s)
- C M Segeren
- Dr. Daniel den Hoed Cancer Center, Department of Hematology, Rotterdam, The Netherlands
| | | | | |
Collapse
|
11
|
Diamond LW, Mishka VG, Seal AH, Nguyen DT. Multiparameter interpretative reporting in diagnostic laboratory hematology. INTERNATIONAL JOURNAL OF BIO-MEDICAL COMPUTING 1994; 37:211-24. [PMID: 7705904 DOI: 10.1016/0020-7101(94)90120-1] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Accurate diagnosis and classification of hematologic malignancies (acute leukemias and chronic lymphoproliferative disorders) requires a multiparameter approach including peripheral blood analysis, bone marrow examination, and immunophenotyping. We have designed knowledge-based computer systems for interpretation of the hemogram and peripheral blood smears, analysis of flow cytometric immunophenotyping panels, and morphologic assessment of bone marrow specimens. The 3 modules share a relational database which includes pertinent clinical history in addition to the laboratory results. The bone marrow module automatically writes a complete interpretative report with a final diagnosis by searching all of the databases for appropriate clinical, peripheral blood, and immunophenotyping information. The ability of the 3 modules to interact, and the quality of the interpretative reports were tested on 100 consecutive patients with leukemia. The final diagnosis made by the bone marrow system agreed with the hospital diagnosis in 94 cases and the authors' interpretation in 99 of 100 cases.
Collapse
Affiliation(s)
- L W Diamond
- Institut für Pathologie der Universität zu Köln, Germany
| | | | | | | |
Collapse
|
12
|
Ludwig WD, Raghavachar A, Thiel E. Immunophenotypic classification of acute lymphoblastic leukaemia. BAILLIERE'S CLINICAL HAEMATOLOGY 1994; 7:235-62. [PMID: 7803900 DOI: 10.1016/s0950-3536(05)80201-x] [Citation(s) in RCA: 45] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Affiliation(s)
- W D Ludwig
- Department of Medical Oncology and Applied Molecular Biology, Free University of Berlin, Germany
| | | | | |
Collapse
|
13
|
van't Veer MB, Gratama JW. Quality assessment for immunophenotyping of leukaemias and lymphomas: the Dutch experience. The SIHON Study Group. Leuk Lymphoma 1994; 13 Suppl 1:77-9. [PMID: 8075586 DOI: 10.3109/10428199409052680] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Sending material at regular intervals to laboratories that perform immunophenotyping of leukaemias and lymphomas showed a large variety in the percentage of positive cells between the different laboratories but an agreement in diagnosis of more than 90%. Each laboratory used his own methods but antibody panels and guide-lines for interpretation were standardised. Studies are in progress to answer the question if standardisation in flow cytometry will result in more comparable results.
Collapse
|
14
|
van't Veer MB, van Putten WL, Verdonck LF, Ossenkoppele GJ, Löwenberg B, Kluin-Nelemans JC, Wijermans PW, Schouten HC, Sizoo W, Dekker AW. Acute lymphoblastic leukaemia in adults: immunological subtypes and clinical features at presentation. Ann Hematol 1993; 66:277-82. [PMID: 7686403 DOI: 10.1007/bf01695969] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
In 91 of 106 adult patients with acute lymphoblastic leukemia (ALL) enrolled in the treatment protocol ALL HOVON-5 between May 1988 and October 1991, the immunophenotype of the leukemia was determined and correlated with clinical characteristics at presentation. The immunological marker analysis was performed in ten laboratories, all members of the Dutch Study Group on Immunophenotyping of Leukemias and Lymphomas (SI-HON). Undifferentiated blasts were found in four patients, 67 had B-lineage ALL, 18 had T-lineage ALL, and two had biphenotypic ALL. The age of T-lineage ALL patients was lower (mean 29.3) than that of B-lineage ALL patients (mean 35.5). Tumor mass, as expressed by leukocyte count, organomegaly, and LDH, was more pronounced in T-lineage ALL. Hemoglobin and platelet count was similar in all (sub)types. CD34 was expressed in 58% of the leukemias, but most frequently in the common B-ALL (70%). Thirteen percent of the leukemias expressed one or more markers not associated with their lineage. In this prospective study immunological data were not evaluable for 15 patients. On four of them data were not available because of dry tap, for six patients the typing was technically insufficient, and for four patients the results were unclassifiable; with one patient the marker analysis was not performed.
Collapse
Affiliation(s)
- M B van't Veer
- Department of Hematology, Dr. Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
| | | | | | | | | | | | | | | | | | | |
Collapse
|